The slow but steady march toward more individualized care in cancer medicine has left pancreatic cancer behind. Patients diagnosed with this disease live no longer today than patients diagnosed 2 decades ago, despite more than a dozen large clinical trials. Even as many patients with other cancers have benefited from targeted drugs like imatinib (Gleevec) and trastuzumab (Herceptin), pancreatic cancer remains as deadly as ever. Read more > >
by Dr. Cathy Backinger
With the enactment of the Family Smoking Prevention and Tobacco Control Act on June 22, the United States entered a new era in tobacco control and prevention. While the importance of the new law cannot be overstated, it is only one component of a much larger, comprehensive tobacco control and prevention agenda, for which NCI-supported science is critically important. This issue of the NCI Cancer Bulletin highlights several important tobacco control research studies supported by NCI.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at firstname.lastname@example.org.